RE:RE:Where is Amg63usaTo be fair, AMG dished it out more than most on this board, and then flipped a 180, which makes me think investors shouldn’t be moderators. Do miss all those “Come on AGN” videos, though.
For those who think AGN is all about COVID-19, think again. There’s more to be had in treating chronic diseases and the Company is going to start Phase 2 Human trials this quarter (unless I’ve missed a release) on IPF/chronic cough. Should (and that’s an if) the trials show success in Q4/Q1, there’ll be interest from Big Pharma.
Why are Phase 2 human trials significant? Because 90% of drugs don’t make it to Phase 1 and it’s where valuations of companies can go ballistic.
If the COVID-19 trials are successful, no doubt investors will do 1+1 = 3 and think the IPF trials will be a sure thing and the stock will be in outer space. Then they’ll see treatments for IBD and Nash are just behind and assume automatic success, again.
That’s a best cases scenario, so do your own DD.
My best guess: If the IPF study is successful, it might not be big enough for a $1bn sale but could be worth low-mid $100’s of millions and enough to fund Phase 2 human trials of IBD and Nash. They could also partner with Big Pharma to further develop, or use that IPF success to leverage the potential value of their IBD and Nash treatments and sell for a higher figure.
As for C19, there’ll be more than one treatment, and before a safe vaccine is available.